Compare Starbucks Corp (SBUX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs TransMedics Group Inc — how do they compare? Starbucks Corp trades at $92.51 (market cap $106.26B), while TransMedics Group Inc trades at $77.5 (market cap $2.74B). The key difference: Starbucks Corp is far larger — about 38.8× TransMedics Group Inc's market cap, and Starbucks Corp pays a 2.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and TransMedics Group Inc for 24 Days on average.
| SBUX | TMDX | |
|---|---|---|
Market Cap | $106.26B | $2.74B |
Volume | 30,248,434 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $150.42 |
52-Week Low | $78.46 | $61.99 |
Typical Hold Time | 190 Days | 24 Days |
Enterprise Value | $125.08B | $3.13B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $91.66, down 2.05% amid a bearish technical outlook with support at $89 and resistance at $92. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $0.85 vs. $0.66, but Q4 2025 missed at $0.56. Recent news highlights store closures and restructuring charges of approximately $300 million as part of a strategic turnaround. Revenue growth remains modest at $37.18B for 2025, with net income margin at 5.17%.
The stock presents a cautious opportunity with analyst consensus price target of $115.50 implying 26% upside, though high P/E of 53.88 raises valuation concerns. Key risks include execution of store optimization, labor relations, and geopolitical tensions in China. Institutional sentiment is divided with 47% buy ratings, but technical indicators signal near-term pressure.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
